For Physicians. By Physicians.™
For Physicians. By Physicians.™
In December 2020, the US Congress passed the ‘No Surprises Act’, which is in effect as of January 2022. The purpose of this legislation is to protect patients from surprise medical bills that may occur when an individual unknowingly receives care from an out-of-network practitioner at an in-network health care facility. The law also establishes a method of determining payments made by a patient’s insurer to the out-of-network practitioner. Insurers and practitioners must first negotiate out-of-network rates. If negotiations fail, they may proceed to a federal independent dispute resolution (IDR) process in which each party submits a price, and an arbitrator decides using the insurer’s median in-network rate as a benchmark.
Before the No Surprises Act, 18 states had enacted their own surprise billing legislation.
Using anesthesia services, researchers (JAMA Internal Medicine) conducted a retrospective economic analysis of data from 2014 to 2017 from three states, California, Florida, and New York, comparing price changes before and after with 45 states that had not passed such ‘surprise bill’ legislation. Anesthesiology is one of the specialties with a great potential for surprise bills because patients typically do not choose an anesthesiologist for service.
Each of the three study states used a different payment standard or independent dispute resolution to determine the out-of-network rate paid to practitioners. The data set to examine the effect of the law had short before and after periods. Finally, not all commercial claims were examined, only claims from three of the largest US insurers.
The researchers learned that compared to prices in the control state, prices paid to in-network and out-of-network anesthesiologists in hospital outpatient departments and ambulatory surgery centers declined after surprise-billing legislation was enacted in the study states. California practitioners have argued that out-of-network prices were too low compared to in-network prices. Florida saw the largest out-of-network decline but that may have occurred because those prices were already substantially higher than those of in-network prices.
In summary, state surprise-billing legislation directly lowered anesthesia out-of-network prices and indirectly lowered in-network prices in outpatient departments and ambulatory surgery centers. These findings, however, cannot necessarily be extrapolated to other specialties. Data collection will need to continue to have more comprehensive information over a longer period of time.
Take a post-test and get CME credits
TAKE THE POST TESTPlease log in to ObGFirst to access this page
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
